In vivo, patients with active pulmonary TB displayed thrombocytosis and increased fibrinogen, factor VIII, and plasminogen activator inhibitor 1 plasma levels, associated with depressed antithrombin III and protein C levels in the first month of treatment, resulting in activated coagulation and inhibited fibrinolysis [26]. This evidence concerns the gene SERPINC1 and thrombocytosis disease.